SCHEMBL6822091

SCHEMBL6822091

CC(C)n1nc(-c2c(-c3ccccc3)nn3cccc(O)c23)ccc1=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.41
TP53 P04637 2/20 0.37
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
BMPR1B O00238 1/20 0.33
BMPR1A P36894 1/20 0.33
TGFBR1 P36897 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
HSD11B1 P28845 1/20 0.33
IGF1R P08069 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824757 0.85 ADORA1 (0.38) ADORA1TP53ALDH1A1MEN1KMT2A
SCHEMBL6822356 0.83 ADORA1 (0.43) ADORA1TP53POLBMEN1KMT2A
SCHEMBL6821956 0.82 ADORA1 (0.39) ADORA1TP53ALDH1A1KDM4EHRH3
SCHEMBL7039587 0.81 ADORA1 (0.57) ADORA1IGF1R
SCHEMBL6825137 0.81 ADORA1 (0.36) ADORA1TP53POLBBMPR1BBMPR1A
SCHEMBL6821908 0.81 ADORA1 (0.38) ADORA1ALDH1A1SMN1; SMN2KDM4EHRH3
SCHEMBL6822009 0.79 ADORA1 (0.45) ADORA1TP53POLBKMT2ASMN1; SMN2
SCHEMBL6822507 0.78 HTR7 (0.38) ADORA1TP53ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6818684 0.78 ADORA1 (0.35) ADORA1TP53POLBALDH1A1MEN1
SCHEMBL6824772 0.78 ADORA1 (0.44) ADORA1TP53POLBKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885TP53 4085/4885POLB 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.